96 related articles for article (PubMed ID: 8713686)
1. Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI-988.
Romani R; Howes LG; Morris DL
Clin Exp Pharmacol Physiol; 1996 May; 23(5):438-40. PubMed ID: 8713686
[TBL] [Abstract][Full Text] [Related]
2. Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro.
Romani R; Howes LG; Morris DL
Aust N Z J Surg; 1996 Apr; 66(4):235-7. PubMed ID: 8611133
[TBL] [Abstract][Full Text] [Related]
3. Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells.
Stepan VM; Sawada M; Todisco A; Dickinson CJ
Mol Med; 1999 Mar; 5(3):147-59. PubMed ID: 10404512
[TBL] [Abstract][Full Text] [Related]
4. [Gastrin-17 and G17-gly induce proliferation of LoVo cells through the CCK B/gastrin receptor].
Artru P; Attoub S; Levasseur S; Lewin MJ; Bado A
Gastroenterol Clin Biol; 1998; 22(6-7):607-12. PubMed ID: 9762332
[TBL] [Abstract][Full Text] [Related]
5. CI-988 inhibits growth of small cell lung cancer cells.
Moody TW; Jensen RT
J Pharmacol Exp Ther; 2001 Dec; 299(3):1154-60. PubMed ID: 11714907
[TBL] [Abstract][Full Text] [Related]
6. Growth of colorectal carcinoma cells: regulation in vitro by gastrin, pentagastrin and the gastrin-receptor antagonist proglumide.
Imdahl A; Eggstein S; Crone C; Farthmann EH
J Cancer Res Clin Oncol; 1989; 115(4):388-92. PubMed ID: 2760104
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
8. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
[No Abstract] [Full Text] [Related]
9. Influence of gastrin on human astrocytic tumor cell proliferation.
Camby I; Salmon I; Danguy A; Pasteels JL; Brotchi J; Martinez J; Kiss R
J Natl Cancer Inst; 1996 May; 88(9):594-600. PubMed ID: 8609660
[TBL] [Abstract][Full Text] [Related]
10. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder.
Sramek JJ; Costa JF; Adams JB; Macpherson A; Cutler NR
Anxiety; 1994-1995; 1(5):242-3. PubMed ID: 9160582
[No Abstract] [Full Text] [Related]
11. Gastrin: growth enhancing effects on human gastric and colonic tumour cells.
Watson S; Durrant L; Morris D
Br J Cancer; 1989 Apr; 59(4):554-8. PubMed ID: 2713241
[TBL] [Abstract][Full Text] [Related]
12. Identification of gastrin as a growth peptide in human pancreatic cancer.
Smith JP; Fantaskey AP; Liu G; Zagon IS
Am J Physiol; 1995 Jan; 268(1 Pt 2):R135-41. PubMed ID: 7840313
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
14. Divergent proliferative responses to a gastrin receptor ligand in synchronized and unsynchronized rat pancreatic AR42J tumour cells.
Bestervelt L; Barr B; Dethloff L
Cell Signal; 2000 Jan; 12(1):53-61. PubMed ID: 10676848
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
17. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
18. Gastric gland degeneration induced in monkeys by the CCK-B/gastrin receptor antagonist CI-988.
Dethloff LA; Robertson DG; Tierney BM; Breider MA; Bestervelt LL
Toxicol Pathol; 1997; 25(5):441-8. PubMed ID: 9323831
[TBL] [Abstract][Full Text] [Related]
19. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
Rohlff C; Watson SA; Morris TM; Skelton L; Jackman AL; Page MJ
Cancer Res; 1999 Mar; 59(6):1268-72. PubMed ID: 10096558
[TBL] [Abstract][Full Text] [Related]
20. Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism.
Watson SA; Clifford T; Sykes RE; Robinson E; Steele RJ
Eur J Cancer; 1995 Nov; 31A(12):2086-92. PubMed ID: 8562170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
